The European Commission Approves Astellas’ XOSPATA® for Patients with Relapsed or Refractory Acute Myeloid Leukemia with a FLT3 Mutation Detected by Validated Tests, including the Invivoscribe LeukoStrat CDx FLT3 Mutation Assay
05. Dezember 2019 06:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Dec. 05, 2019 (GLOBE NEWSWIRE) -- For twenty-five years, Invivoscribe has improved the quality of healthcare worldwide by providing high quality, standardized reagents, tests, and...
US FDA approves Invivoscribe LeukoStrat CDx FLT3 Mutation Assay as CDx and Astellas drug XOSPATA (gilteritinib fumarate) for treatment of AML patients in the US
29. November 2018 06:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 29, 2018 (GLOBE NEWSWIRE) -- Invivoscribe is pleased to announce FDA approval of both the LeukoStrat CDx FLT3 Mutation Assay and the Astellas drug, XOSPATA (gilteritinib fumarate),...
Invivoscribe Submits the LeukoStrat CDx FLT3 Mutation Assay to Support Daiichi Sankyo Submission for Quizartinib in Japan
19. November 2018 08:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Nov. 19, 2018 (GLOBE NEWSWIRE) -- In support of an ongoing partnership with Daiichi Sankyo, Invivoscribe is pleased to announce submission of the LeukoStrat® CDx FLT3 Mutation Assay to...
Invivoscribe® Receives Approval in Japan for its LeukoStrat® CDx FLT3 Mutation Assay to Assess Acute Myeloid Leukemia (AML) Patients Eligible for Treatment with Xospata® (gilteritinib fumarate)
27. September 2018 06:00 ET
|
Invivoscribe, Inc.
SAN DIEGO, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Invivoscribe® Inc., a global company providing biomarker and clonality test solutions for the fields of oncology and personalized molecular medicine®...
Invivoscribe FLT3 Testing Patents Strengthened by Supreme Court Ruling
19. Juni 2013 08:36 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwired - Jun 19, 2013) - In Association of Molecular Pathology v. Myriad, the U.S. Supreme Court struck down BRCA1 and BRCA2 gene patent claims. It is important for the...
Invivoscribe Announces Collaboration Agreement to Develop Companion Diagnostic Test
15. Februar 2011 16:00 ET
|
Invivoscribe Technologies, Inc.
SAN DIEGO, CA--(Marketwire - February 15, 2011) - Invivoscribe™ Technologies, Inc., a world leader in personalized molecular medicine, announced today that they have entered into a...